CClinicalTrials.gg
CompletedNCT02282774Updated Nov 4, 2014

Subtenon Block Combined With General Anesthesia for Vitreoretinal Surgery

A Phase 3 interventional study of 2% lidocaine and 0.5% bupivacaine and Sham subtenon block in Subtenon Anesthesia, sponsored by King Saud University. Completed at 1 site in Saudi Arabia. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-11-04.

Sponsored by King Saud University · Phase 3, Interventional, and Supportive care

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years to 90 Years
Sex
All
01

Study summary

To evaluate the effects of subtenon block (SB) as an adjunct to general anaesthesia on postoperative pain, oculocardiac reflex and postoperative nausea and vomiting for vitreoretinal surgery.

02

Conditions studied

  • Subtenon Anesthesia

Keywords

  • Vitreoretinal surgery
03

In context

Lead sponsor

King Saud University is the lead sponsor of 164 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient undergoing elective retinal surgery under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • ASA physical status > Grade II,
  • psychiatric conditions,
  • neurological impairment,
  • deafness with whom communication would be difficult in the postoperative period,
  • clotting abnormalities,
  • contraindications for regional anesthesia,
  • drug abuse,
  • history of allergy to the study drugs,
  • previous vitreoretinal or strabismus surgery,
  • endophthalmitis, or inflammatory eye pathology
  • taking analgesics, antiemetics or drugs that might affect hemodynamics
05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    SB

    receive subtenon block of 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture

    Drug: 2% lidocaine and 0.5% bupivacaine

  • Sham comparator
    C

    receive subtenon block of 4mL saline

    Drug: Sham subtenon block

Interventions

  • Drug2% lidocaine and 0.5% bupivacaine

    Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed

  • DrugSham subtenon block
06

What researchers measure

Primary outcomes

  1. the time to first postoperative analgesic dose

    Pain was evaluated using a VNS chart (0-no pain at all, 10-the worst pain imaginable) at 30 min, 1, 2, 4, 6, 12,18 and 24 hours postoperatively. During PACU stay, if the patient complain of pain postoperatively (VNS ≥ 4), morphine boluses of 25 µg /kg (injected at 10-min intervals) was administered intravenously if requested until the pain subsided for a maximum dose of 10 mg. At the end of 2 h, the patients were transferred from the PACU to the ward where the pain was assessed, paracetamol 15 mg/kg was given intravenously and was repeated every 4 hours if needed in the ward by a nurse who is blinded to the study group as paracetamol is the standard post-operative pain medication for patients undergoing ophthalmic surgery at our institute. Time to first post-operative analgesic, which is the time, elapsed between end of the surgical procedure and first administration of an analgesic was noted

    Time frame: 24 hrs

Secondary outcomes

  1. postoperative pain scores

    Pain was evaluated using a VNS chart (0-no pain at all, 10-the worst pain imaginable) at 30 min, 1, 2, 4, 6, 12,18 and 24 hours postoperatively. During PACU stay, if the patient complain of pain postoperatively (VNS ≥ 4), morphine boluses of 25 µg /kg (injected at 10-min intervals) was administered intravenously if requested until the pain subsided for a maximum dose of 10 mg. At the end of 2 h, the patients were transferred from the PACU to the ward where the pain was assessed, paracetamol 15 mg/kg was given intravenously and was repeated every 4 hours if needed in the ward by a nurse who is blinded to the study group as paracetamol is the standard post-operative pain medication for patients undergoing ophthalmic surgery at our institute. Time to first post-operative analgesic, which is the time, elapsed between end of the surgical procedure and first administration of an analgesic was noted.

    Time frame: First 24 hrs after surgery

  2. number of patients requiring rescue analgesics during the 24-h study period

    Time frame: during the whole study (6 months)

  3. consumption of rescue analgesics

    The total number of patients receiving rescue analgesia is recorded

    Time frame: during the whole study (6 months)

  4. incidence of oculocardiac reflex

    Time frame: during time of surgery

  5. incidence of postoperative nausea/vomiting

    The incidence of postoperative nausea and vomiting (PONV) was assessed by a nurse (who was blinded to the study drug) for the first 2 h in the PACU and subsequently in the ward at 6, 12 and 24 h and Only 2 possible answers was accepted (yes) or (no). Nausea was defined as subjective sensation of discomfort associated with the awareness of the urge to vomit. Vomiting was defined as a forceful expulsion of gastric contents through the mouth. Rescue antiemetic (Ondansetron 0.15 mg/kg) was given if the patient had persistent nausea or more than a single episode of vomiting or whenever patients request medication and number of patients required rescue anti-emetic postoperatively were recorded

    Time frame: First 24 hrs after surgery

07

Study locations

1 site
  • King Abdulaziz University Hospital at King Saud University
    Riyadh, 11411, Saudi Arabia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02282774
Lead sponsor
King Saud University
Responsible party
Marwan Abouammoh (Associate professor, King Saud University) — Principal investigator
First posted
Nov 4, 2014
Start date
Dec 2013
Primary completion
Jun 2014
Last update
Nov 4, 2014

Study contacts

Marwan Abouammoh, MD
principal investigator · King Saud University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion